Cancer drug developer Nuvalent jumps 39% after GSK agrees to buy it for $10.6 billion

British pharmaceutical company GSK announced it will acquire cancer drug developer Nuvalent for $10.6 billion. This deal caused Nuvalent's stock to surge 39% as investors reacted positively to the acquisition. The move highlights GSK's strategic investment in cancer treatments, potentially strengthening its position in the oncology market. Further details on the deal's impact and timeline are expected as the acquisition progresses.